Benzoyl peroxide is a Small Molecule owned by Sol-Gel Technologies, and is involved in 4 clinical trials, which were completed.
Benzoyl peroxide is a encapsulated benzoyl peroxide (E-BPO). Benzoyl peroxide has a keratolytic and desquamative effect which may also contribute to its efficacy. Benzoyl peroxide gets absorbs by the skin where it is converted to benzoic acid. The active ingredient migrates through the pores of the microcapsules while the barrier improves tolerability of the active ingredient.
The revenue for Benzoyl peroxide is expected to reach a total of $578m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Benzoyl peroxide NPV Report.
Benzoyl peroxide is currently owned by Sol-Gel Technologies.
Benzoyl peroxide Overview
Benzoyl peroxide (Epsolay) is a peroxide with antibacterial, irritant, keratolytic, comedolytic, and anti-inflammatory activity developed based on Sol-Gel drug delivery technology. It is formuaated as cream for topical application. Epsolay for the treatment of inflammatory lesions of rosacea in adults 18 years of age and older.
Sol-Gel Technologies Overview
Sol-Gel Technologies (Sol-Gel) is a dermatology company that carries out the identification, development and commercialization of investigational and generic topical drug products for the treatment of skin diseases. The company provides products under the brand name EPSOLAY for the treatment of inflammatory lesions of rosacea in adults and TWYNEO for the treatment of acne vulgaris. It also offers SGT-210, SGT-310 and SGT-510 drug candidates to treat plaque psoriasis and other dermatologic indications. Sol-Gel utilizes silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs. It operates in the US and Israel. Sol-Gel is headquartered in Ness Ziona, Israel.
The company reported revenues of (US Dollars) US$31.3 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$8.8 million in FY2020. The operating profit of the company was US$3 million in FY2021, compared to an operating loss of US$30.2 million in FY2020. The net profit of the company was US$3.2 million in FY2021, compared to a net loss of US$29.3 million in FY2020. The company reported revenues of US$0.3 million for the third quarter ended September 2022, a decrease of 92.6% over the previous quarter.
Quick View – Benzoyl peroxide
|Highest Development Stage|